Lihua Sun

Prof. Lihua Sun

School of Business Administration, Shenyang Pharmaceutical University, Shenyang, Liaoning, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
LZLingli Zhang
Lingli Zhang
LSLihua Sun
Lihua Sun
Purpose: Currently, China is piloting diagnosis-related groups (DRG) payment system in 30 cities. The main aim of this study was to explore the respondents’ impressions regarding the hospitals’ policies and physicians’ behavior change brought by the DRG payment system, and investigate whether and how the hospitals’ policies affect the physicians’ behavior. Methods: We distributed questionnaires designed for this study to 200 physicians. Data analysis consisted of descriptive statistics, T-test, and network analysis. Results: Respondents stated that the hospitals had adopted several policies in response to DRG payment and DRG payment could reduce overtreatment and improve efficiency. However, it also led to several negative effects including an increased explanation to the patients, hindering new technologies, case splitting, and cherry picking. In addition, there was no evidence that harmful effects such as refusing patients and premature discharge existed. Overall, the benefits outweighed the drawbacks of DRG. Moreover, the hospitals’ policies could effectively change physician behaviors. Our results indicated that promoting the implementation of clinical pathways had the most positive impact, while limiting costs and length of stay is not recommended. Conclusion: In general, Chinese physicians who participated in the questionnaire possessed relatively positive attitudes towards the DRG payment system. Nevertheless, some of the negative impacts cannot be ignored. Meanwhile, the hospitals’ policies should be implemented with adequate consideration of the impact on physicians’ behavior.

5 October 2022 in The Breast
Verified
Journal Article
Open access
SLShiqi Li
Shiqi Li
YZYing Zhang
Ying Zhang
PZPeigen Zhang
Peigen Zhang
SXShuijing Xue
Shuijing Xue
YCYu Chen
Yu Chen
RYRui Yang
Rui Yang
This meta-analysis assessed the predictive and prognostic value of tumor infiltrating lymphocytes (TILs) in neoadjuvant chemotherapy (NACT) treated breast cancer and an optimal threshold for predicting pathologic complete response (pCR). A systematic search of PubMed, EMBASE and Web of Science electronic databases was conducted to identify eligible studies published before April 2022. Either a fixed or random effects model was applied to estimate the pooled hazard ratio (HR) and odds ratio (OR) for prognosis and predictive values of TILs in breast cancer patients treated with NACT. The study is registered with PROSPERO (CRD42020221521). A total of 29 published studies were eligible. Increased levels of TILs predicted response to NACT in HER2 positive breast cancer (OR = 2.54 95%CI, 1.50–4.29) and triple negative breast cancer (TNBC) (OR = 3.67, 95%CI, 1.93–6.97), but not for hormone receptor (HR) positive breast cancer (OR = 1.68, 95 %CI, 0.67–4.25). A threshold of 20% of H & E-stained TILs was associated with prediction of pCR in both HER2 positive breast cancer (P = 0.035) and TNBC (P = 0.001). Moreover, increased levels of TILs (either iTILs or sTILs) were associated with survival benefit in HER2-positive breast cancer and TNBC. However, an increased level of TILs was not a prognostic factor for survival in HR positive breast cancer (pooled HR = 0.64, 95%CI: 0.03–14.1, P = 0.78). Increased levels of TILs were associated with increased rates of response to NACT and improved prognosis for the molecular subtypes of TNBC and HER2-positive breast cancer, but not for patients with HR positive breast cancer. A threshold of 20% TILs was the most powerful outcome prognosticator of pCR.

5 June 2023 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
LHLi Huang
Li Huang
XPXiaochen Peng
Xiaochen Peng
LSLihua Sun
Lihua Sun
DZDawei Zhang
Dawei Zhang
The objective of this study was to estimate the willingness to pay (WTP) per quality-adjusted life year (QALY) among people with malignancies in China. The WTP for a QALY was estimated using a contingent valuation survey. Health utility was measured in EuroQol-5 dimensions (EQ-5D). The questionnaires were completed in face-to-face interviews. Respondents consisted of patients with malignant tumors and their family members and came from three tertiary hospitals in different cities with high, medium, and low gross domestic product (GDP) levels. In this study, we offered lump-sum payments and 10 year installment plans to respondents. Finally, we conducted sensitivity analysis and stepwise regression analyses to identify factors that affected the WTP/QALY ratios. A total of 1264 people participated in this survey, and 1013 people gave WTP responses for further analysis. The mean and median WTP/QALY values based on the lump-sum payments were 366,879 RMB (53,171USD, 5.1 times the GDP per capita) and 99,906 RMB (14,479USD, 1.39 times the GDP per capita) for the overall sample; 339,330 RMB (49,178USD, 4.71 times the GDP per capita) and 83,875 RMB (12,156USD, 1.16 times the GDP per capita) for the patient group; and 407,396 RMB (59,043USD, 5.66 times the GDP per capita) and 149,436 RMB (21,657USD, 2.08 times the GDP per capita) for the family group. Considering the skewedness of the data distribution, we suggest setting the cost-utility threshold with reference to the median. When the payment plan changed to 10-year installments, the median increased to 134,734RMB (19,527USD), 112,390 RMB (16,288USD) and 173,838 RMB (25,194USD) for the above groups, respectively. EQ-5D-5L health utility, annual household income per capita, patients with other chronic diseases, occupation, regular physical examinations (patients) and age (family members) were significantly related to WTP/QALY. This study provides empirical evidence of the monetary value of a QALY from a sample of the Chinese population with malignancies. In addition, the ratio of the WTP/QALY to GDP per capita was related to the disease and hypothetical scenario, and a higher ratio of GDP per capita for malignant tumor therapies should be considered.

3 October 2023 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
LSLihua Sun
Lihua Sun
XPXiaochen Peng
Xiaochen Peng
SLShiqi Li
Shiqi Li
ZHzhe huang
zhe huang
The use of multiple cost-effectiveness thresholds in pharmacoeconomic evaluation is a hotly debated topic in the international academic community. This study analyzed and discussed thresholds in the context of pharmacoeconomic evaluation and reimbursement decision-making. We suggest that the thresholds inferred from reimbursement decisions should be distinguished from cost-effectiveness threshold in pharmacoeconomic evaluation. Pharmacoeconomic evaluations should adopt a fixed threshold, which should not vary with the subjects evaluated. This would help avoid the invitation of numerous cost-effectiveness thresholds for a specific drug, an exceptional disease, a type of innovation, or a certain level of malignancy, which misleads economic evaluation adopting restless changing standards and making pharmacoeconomic evaluation and decision-making more complex and contradictory.

30 July 2024 in BMC Public Health
Verified
Journal Article
Open access
PDF file
YLYipeng Lan
Yipeng Lan
XLXiaofeng Lin
Xiaofeng Lin
QCQiannan Chen
Qiannan Chen
LWLi Wang
Li Wang
LSLihua Sun
Lihua Sun
ZHzhe huang
zhe huang
Background: Drug shortage is a worldwide problem that seriously threatens public health. China released the most comprehensive list of key drug shortage monitoring varieties ever in 2022. We aim to analyze the attributes and characteristics of the medicines within the list to provide a reference for improving China’s supply security of shortage drugs. Methods: We used public data to extract information on drug types, dosage forms, indications, classification of clinical uses, whether they were included in medical catalogs such as the National Essential Drugs, and the number of drug and active pharmaceutical ingredient (API) manufacturers. A descriptive statistical analysis was used. Results: Of the 980 drugs on the list, 99.59% were chemicals and 92.65% were injectables. Drugs for blood and hematopoietic organs, the cardiovascular system, and the digestive tract and metabolism ranked among the top three shortages. Verification of the medical catalogs showed that 90.41% of the drugs belonged to the national essential drugs, 95.10% were medicare drugs, 2.55% were volume-based procurement drugs, and 14.70% were for rare diseases, and 42.04% were for children. In terms of drug supply capacity, 21.33% of drug approvals are less than 10, and there were even 26 drugs for exclusive production, close to 90% of manufacturers need to purchase APIs from outside. Among the 256 APIs included in the list, 152 APIs had less than 10 manufacturers, and there were even 5 APIs produced by only one enterprise nationwide. Conclusions: The situation of drug shortages in China was severe and complex, with serious shortages of medicines adapted to basic medical and healthcare needs and clinically necessary medicines, and a need to improve the production capacity of drugs and the ability to supply APIs. We recommend strengthening drug monitoring and stockpiling and accelerating the approval of shortage drugs to improve drug supply security.

8 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
QSQiang Su
Qiang Su
YZYumeng Zhang
Yumeng Zhang
YSYuanhao Sui
Yuanhao Sui
LSLihua Sun
Lihua Sun
DZDawei Zhang
Dawei Zhang
The issue of regional disparities in medical resources and insurance benefits is notably prevalent in China. As a result, seeking medical treatment across regions has emerged as a focal point of health reform efforts in recent years. This study examines the impact of outpatient settlement for cross-regional medical treatment on healthcare choices by the floating population who live and work in regions different from their registered residence. Using data from the China Family Panel Studies (CFPS), this study conducts an empirical analysis through Propensity Score Matching and Difference-in-Differences (PSM + DID). The analysis included a sample of 3,019 floating population from 2012 to 2020. The findings indicate that they are significantly more inclined to select advanced medical institution (coefficient = 0.252, p < 0.05) due to the influence of the policy. Furthermore, heterogeneity analysis reveals that this policy primarily affects the labor force (coefficient = 0.268, p < 0.05) and urban residents (coefficient = 0.286, p < 0.05) within the floating population. Ultimately, the outpatient settlement for cross-regional medical treatment affects the floating population to seek care at advanced medical institution, which conflicts with the objectives of the hierarchical medical system. Policymakers should enhance communication to ensure better coordination between these policies.